


FIG. 1



Safety Assessment (Primary)
1
4
8
12
16
20
24
28
32
36*
40
44
48
52*
Baseline
Plasma CSF GL-1 (Exploratory)
MDS-UPDRS parts II and III* (Exploratory)
End of Week 4
Plasma CSF PK (Secondary)
Plasma CSF GL-1 (Exploratory)
End of Week 8
MDS-UPDRS parts II and III* (Exploratory)
Randomisation
Completed Study (ROW)
Completed Study (Japan)
Placebo N=4 (ROW) / N=3 (Japan)
N=4
N=3
Compound 2 PO, qd
Low dose N=4 (ROW) / N=3 (Japan)
Mid dose N=5 (ROW) / N=3 (Japan)
High dose N=4 (ROW) / N=3 (Japan)
N=3
N=5
N=3
N=3
N=3
N=3
Data monitoring committee meeting
Dose escalation decision meeting
Exploratory biomarker assessment

FIG. 2



Low-dose (Japan)
Low-dose (ROW)
Mid-dose (Japan)
Mid-dose (ROW)
High-dose (Japan)
High-dose (ROW)
LLOQ = 0.5 (ng/ml)
Mean (SD)Compound 2Concentration (ng/mL)
200
150
100
50
0
Day 1 (0 hr)
Week 2 (0 hr)
Week 4 (0 hr)
Week 8 (0 hr)

FIG. 3



A. Mean percent change from baseline in plasma GL-1
Japanese Participants
ROW Population
Week 2
Week 4
Mean Percent Change From Baseline (SD)
40
20
0
-20
-40
-60
-80
-100
14.4
3.7
-64.6
-68.
-67.5
-70.
-77.2
-72.
-7.0
3.8
-64.3
-69.6
-69.3
-74.0
-74.9
-77.7
Placebo
Low
Mid
High
Compound 2 Dose
Number of Participants
3 3 3 3 3 3 3 3
4 4 4 4 5 5 4 4
B. Mean percent change from baseline in CSF GL-1
Japanese participants
ROW Population
Week 4
-1.0
-21.7
-57.3
-72.8
12.8
-31.0
-58.6
-74.3
Placebo
Low
Mid
High
Compound 2 Dose
Number of participants
3 3 3 3
4 4 5 3

FIG. 4



A. Mean plasma GL-1 levels
Japanese participants
ROW Population
Baseline
Week 4
Mean GL-1 Level, µg/mL (SD)
Placebo
Low
Mid
High
Compound 2 Dose
Number of participants
B. Mean CSF GL-1 levels
Japanese participants
ROW Population
Baseline
Week 4
Mean GL-1 Level, µg/mL (SD)
Placebo
Low
Mid
High
Compound 2 Dose
Number of participants

FIG. 5